Shira Doron

Shira Doron

Auto-generated profile, based on publicly available information

Shira Doron

Tufts Medical Center

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SDShira Doron
Shira Doron
DSDavid R. Snydman
David R. Snydman
Probiotics have been used safely for years. Safety outcomes are inconsistently reported in published clinical trials. In 2011, a report released by the Agency for Healthcare Research and Quality concluded that, although the existing probiotic clinical trials reveal no evidence of increased risk, “the current literature is not well equipped to answer questions on the safety of probiotics in intervention studies with confidence.” Critics point out that the preponderance of evidence, including the long history of safe probiotic use as well as data from clinical trials, and animal and in vitro studies all support the assumption that probiotics are generally safe for most populations. Theoretical risks have been described in case reports, clinical trial results and experimental models, include systemic infections, deleterious metabolic activities, excessive immune stimulation in susceptible individuals, gene transfer and gastrointestinal side effects. More research is needed to properly describe the incidence and severity of adverse events related to probiotics.

1 June 2013 in Clinical Therapeutics
Verified
Journal Article
Closed access
SDShira Doron
Shira Doron
LNLauren Nadkarni
Lauren Nadkarni
LPLori Lyn Price
Lori Lyn Price
KLKenneth Lawrence
Kenneth Lawrence
LDLisa E. Davidson
Lisa E. Davidson
DSDavid R. Snydman
David R. Snydman

1 August 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SDShira Doron
Shira Doron
PHPatricia L. Hibberd
Patricia L. Hibberd
BGBarry Goldin
Barry Goldin
CTCheleste Thorpe
Cheleste Thorpe
LMLaura McDermott
Laura McDermott
DSDavid R. Snydman
David R. Snydman
Vancomycin-resistant enterococci (VRE) are endemic in health care settings. These organisms colonize the gastrointestinal tract and can lead to infection which is associated with increased mortality. There is no treatment for VRE colonization. We conducted a randomized, double-blind, placebo-controlled clinical trial to examine the safety and efficacy of administration of the probiotic Lactobacillus rhamnosus GG (LGG) for the reduction or elimination of intestinal colonization by VRE. Colonized adults were randomized to receive LGG or placebo for 14 days. Quantitative stool cultures for LGG and VRE were collected at baseline and days 7, 14, 21, 28, and 56. Day 14 stool samples from some subjects were analyzed by quantitative PCR (qPCR) for LGG. Patients were closely monitored for adverse events. Eleven subjects, of whom 5 received LGG and 6 received placebo, were analyzed. No differences in VRE colony counts were seen at any time points between groups. No decline in colony counts was seen over time in subjects who received LGG. LGG was detected by PCR in all samples tested from subjects who received LGG but was only isolated in culture from 2 of 5 subjects in the LGG group. No treatment-related adverse events were seen. We demonstrated that LGG could be administered safely to patients with comorbidities and is recoverable in some patients' stool cultures. Concomitant administration of antibiotics may have resulted in an inability to recover viable organisms from stool samples, but LGG DNA could still be detected by qPCR. LGG administration did not affect VRE colonization in this study. (This study was registered at Clinicaltrials.gov under registration no. NCT00756262.)

11 January 2016 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
KBKirthana Beaulac
Kirthana Beaulac
Silvia CorcioneSilvia Corcione
Silvia Corcione
LELauren Epstein
Lauren Epstein
LDLisa E. Davidson
Lisa E. Davidson
SDShira Doron
Shira Doron
OBJECTIVE: To offer antimicrobial stewardship to a long-term acute care hospital using telemedicine.METHODS: We conducted an uninterrupted time-series analysis to measure the impact of antimicrobial stewardship on hospital-acquired Clostridium difficile infection (CDI) rates and antimicrobial use. Simple linear regression was used to analyze changes in antimicrobial use; Poisson regression was used to estimate the incidence rate ratio in CDI rates. The preimplementation period was April 1, 2010–March 31, 2011; the postimplementation period was April 1, 2011–March 31, 2014.RESULTS: During the preimplementation period, total antimicrobial usage was 266 defined daily doses (DDD)/1,000 patient-days (PD); it rose 4.54 (95% CI, −0.19 to 9.28) per month then significantly decreased from preimplementation to postimplementation (−6.58 DDD/1,000 PD [95% CI, −11.48 to −1.67]; P=.01). The same trend was observed for antibiotics against methicillin-resistant Staphylococcus aureus (−2.97 DDD/1,000 PD per month [95% CI, −5.65 to −0.30]; P=.03). There was a decrease in usage of anti-CDI antibiotics by 50.4 DDD/1,000 PD per month (95% CI, −71.4 to −29.2; P<.001) at program implementation that was maintained afterwards. Anti-Pseudomonas antibiotics increased after implementation (30.6 DDD/1,000 PD per month [95% CI, 4.9–56.3]; P=.02) but with ongoing education this trend reversed. Intervention was associated with a decrease in hospital-acquired CDI (incidence rate ratio, 0.57 [95% CI, 0.35–0.92]; P=.02).CONCLUSION: Antimicrobial stewardship using an electronic medical record via remote access led to a significant decrease in antibacterial usage and a decrease in CDI rates.Infect. Control Hosp. Epidemiol. 2016;37(4):433–439

10 October 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
TBTinzar Basein
Tinzar Basein
BGBrad Gardiner
Brad Gardiner
GVGabriela M Andujar Vazquez
Gabriela M Andujar Vazquez
ACAndrew S Joel Chandranesan
Andrew S Joel Chandranesan
ARArthur R Rabson
Arthur R Rabson
DSDavid R Snydman
David R Snydman
Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range PCR, aiming to evaluate performance and determine impact on patient management. Organisms were identified in 21/71 samples. High numbers of polymorphonuclear leukocytes on Gram stain (odds ratio [OR], 4.17; P = .04) and acute inflammation on histopathology (OR, 5.69; P = .02) were significantly associated with a positive result. Management was altered in 18 patients, 11 with positive and 7 with negative results. Overall, broad-range PCR assay had the highest impact in patients with microscopic evidence of inflammation. Physicians ordering this complex, difficult to interpret, and expensive test should carefully consider all available clinical information on an individualized basis to optimize its performance.

1 September 2019 in American Journal of Infection Control
Verified
Journal Article
Closed access
ABAbigail Benudis
Abigail Benudis
SSSamuel Stone
Samuel Stone
ASAfrah S Sait
Afrah S Sait
IMIan Mahoney
Ian Mahoney
LPLori Lyn Price
Lori Lyn Price
SDShira Doron
Shira Doron